GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (BSP:G1LP34) » Definitions » Other Income (Expense)

Galapagos NV (BSP:G1LP34) Other Income (Expense) : R$301 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Galapagos NV Other Income (Expense)?

Galapagos NV's other income expense for the Galapagos NV's pretax income for the three months ended in Mar. 2024 was R$166 Mil. Its other income expense for the trailing twelve months (TTM) ended in Mar. 2024 was R$301 Mil.

Galapagos NV Other Income (Expense) Historical Data

The historical data trend for Galapagos NV's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Other Income (Expense) Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,032.15 -727.74 392.71 286.16 86.84

Galapagos NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.07 51.95 190.09 -106.84 165.70

Galapagos NV Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$301 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galapagos NV  (BSP:G1LP34) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Galapagos NV (BSP:G1LP34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (BSP:G1LP34) » Definitions » Other Income (Expense)
Comparable Companies
XAMS:PHARM XAMS:BAI XAMS:VVY OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX OCSE:GMAB ALNY BGNE BMRN RPRX SRPT SHSE:603392
Traded in Other Exchanges
GLPG:USA GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany GLPG:Austria
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Website
https://www.glpg.com
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Galapagos NV (BSP:G1LP34) Headlines

No Headlines